Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for neurological disorders. They are currently working on several drug candidates, including treatments for fragile X syndrome, seizures associated with tuberous sclerosis complex and infantile spasms, and epilepsies. They are also developing gene therapy for angelman syndrome and a treatment for kinesin-family of proteins associated neurological disorder. Ovid Therapeutics has license and collaboration agreements with various organizations and was founded in 2014, with headquarters in New York.